Previously, Qi et al. (20) suggested that reducing 12α-hydroxylated BAs and increasing intestinal Tauro-β-MCA, an antagonist of FXR, may reduce high fat diet-induced increase of phospholipids, sphingomyelins and ceramides and ameliorate diabetes and obesity. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.